Seeking Alpha: Copa Holdings Looks Undervalued, But Its Markets Likely Haven't Bottomed

Copa Holdings (NYSE:CPA) and Alaska Air (NYSE:ALK) make for an interesting study in contrasts. Both are well-run airlines by most of the metrics that matter, but they operate in very different markets. While Alaska Air continues to benefit from a benign-to-healthy U.S. airline industry environment, Copa is getting crushed by economic turbulence in major markets like Brazil, Venezuela, and Colombia. Since the time of my last article on Copa, the shares have fallen more than 40% while Alaska Air's shares have climbed nearly 25%. That Copa has outperformed GOL (NYSE:GOL) and Avianca (NYSE:AVH) is true, but doesn't put any money back into shareholders' pockets.

I do believe that the current share price discounts the long-term value of Copa, but it's hard to make money in the midst of weak reported results and lower expectations. Likewise, it's worth at least asking why investors should expect any meaningful turnaround in Brazil, Venezuela, or Colombia in the near term, as these are all commodity-driven markets that need a combination of higher oil, base metal, and agricultural prices to lead a turnaround.

Read the full article here:

Copa Holdings Looks Undervalued, But Its Markets Likely Haven't Bottomed

Seeking Alpha: Alaska Air Making The Most Of Its Opportunities

I hate avoiding the shares of really good companies just because they look a little pricey, and Alaska Air Group (NYSE:ALK) is a good example of why that is. I liked the company back in February and thought that the shares had upside into the $70s, but the stock has managed to touch the high $80s this year and sits more than 25% higher than when I wrote that last article. Since that time, Alaska Air has continued to compete very effectively - not only withstanding Delta Air Lines' (NYSE:DAL) aggressive expansion in Seattle, but also adding several new routes of its own and leveraging its cost advantages.

And now we come back to the perpetual issue with Alaska Air's shares - valuation. At a 5.5x multiple to EBITDAR, the shares are about fairly valued, while a 6x multiple (still within the bounds of normal for an airline) adds about $8/share to the fair value and bumps the undervaluation up over 10%. Looking at free cash flow, today's price seems to be pricing in mid-to-high single-digit annualized FCF growth from 2015's estimated end point, and that's pretty generous for an airline.

Follow this link for more:
Alaska Air Making The Most Of Its Opportunities

Seeking Alpha: IPG Photonics Still On Top Of A Rising Mountain

I've made no secret of the fact that I like and admire IPG Photonics (NASDAQ:IPGP), and I can't say that the shares haven't rewarded that enthusiasm. Since my first piece for Seeking Alpha on the company, the shares are up more than 60%, trouncing other laser companies like Rofin-Sinar (NASDAQ:RSTI), Coherent (NASDAQ:COHR), and Newport (NASDAQ:NEWP), and beating the NASDAQ by a relatively comfortable margin as well.

When I last wrote about the company, the business was running quite smoothly, but I was concerned about the expectations baked into the valuation. The shares have been more or less flat since then on a "net" basis, but I did suggest that investors could look for dips into the $80s as buying opportunities and investors got two such chances (including a move into the $70s).

Now what? I still like this business, and I think IPG Photonics is poised for a decade of revenue growth that averages out to around 9% to 10% a year coupled with excellent free cash flow margins. I do have some worries about the potential of "peak margin", as well as the possibility that IPG Photonics' growth will make it more susceptible to the vagaries of the machine tool cycles, but no stock comes without risks. The shares do look a little undervalued now, but I'd be tempted to try another "buy the dip" move given the macro uncertainties.

Continue here:
IPG Photonics Still On Top Of A Rising Mountain

Seeking Alpha: Manitex Struggling As The Boom Cycle Goes Bust

It's cold comfort when one of the nicest things you can say about a long call is that the company's peers have gotten hammered about the same in the intervening time. Manitex (NASDAQ:MNTX) borrowed extensively to fund an M&A program that has taken the company from around $100 million a year in revenue in 2010 to almost $100 million a quarter now, but the severe downturn in the energy market has hammered this company and pushed operating margins back into the low single digits. Although I think Manitex could still pay its interest even with a 10% sales decline next year and negative gross margin leverage, the situation is far from ideal today.

This is not just a Manitex-specific problem. Manitowoc (NYSE:MTW) is down about as much since the last time I wrote about Manitex, and Terex (NYSE:TEX) has done worse. Europe's Manitou (OTC:MAOIF), which is largely screened from the energy-related downturn in the U.S., hasn't done much better either.

At the risk of not knowing when to quit, I think Manitex still has a worthwhile future. The company's acquisition of PM Group gives the company better exposure to what should be an improving European construction sector in 2016, not to mention exposure to growth in North America (where PM Group has been historically under-represented). I think it's early (or at least very aggressive) to expect an energy recovery, but PM Group and ASV do at least give Manitex more leveraging to a healthier construction sector in North America.

Read the full article here:
Manitex Struggling As The Boom Cycle Goes Bust

Seeking Alpha: Persistent Sluggishness In The U.S. A Growing Problem For First Cash Financial

It's getting harder and harder to give First Cash Financial (NASDAQ:FCFS) the benefit of the doubt. While the currency issues that are pressuring the reported revenue from the company's large Mexican operations are arguably forgivable, the persistent sluggishness in the U.S. operations is harder to excuse. What's worse, I don't think investors are, or should be, all that happy that the company has committed sizable amounts of capital towards consolidating the slow-growing U.S. pawn market and held off on expanding into faster-growing regions like Colombia and Peru.

Cutting expectations for a stock you've recommended is never fun, and it's even less so when you own the shares yourself. The reality, though, is that First Cash has been a rotten stock over the last year, with the shares down about 30%. While there is still an opportunity for First Cash to generate high single-digit to low double-digit growth in Mexico for years to come and generate better margins from the U.S. operations, this is very much a "show me" story today.

Read more here:
Persistent Sluggishness In The U.S. A Growing Problem For First Cash Financial

Seeking Alpha: JPMorgan's Steady Progress Not Fully Rewarded

It may be boring, but JPMorgan Chase's (NYSE:JPM) ability to deliver on the "blocking and tackling" issues identified by management continues to build value for long-term shareholders of this enormous financial institution. More specifically, JPMorgan's management has managed to reduce its GSIB buffer and make progress on cost reductions while simultaneously driving above-average loan growth.

These improvements have led me to adjust my revenue and earnings targets, as well as the company's risk premium, and those improvements support a higher fair value. JPMorgan definitely has a delicate balancing act to maintain between further reducing its buffers and costs and not alienating customers, not to mention balancing the risk of expanded credit and credit losses, and maintaining leading market share in multiple businesses without getting dragged into a race to the bottom on pricing.

JPMorgan appears to be handling this balancing act with considerable skill. Given that, as well as the higher fair value and a generally "meh" attitude towards banks over the past six months, I think JPMorgan is looking a little more interesting as a new buy.

Read the full article here:
JPMorgan's Steady Progress Not Fully Rewarded

Seeking Alpha: The Going's Getting Tougher - Will ABB Keep Going?

The outlook for industrial companies, particularly early-cycle companies, is looking worse as 2015 draws to a close. While a few sectors look as though they could do well in 2016, many sectors with significant capex spending like mining, energy, trucks, and autos are starting to look weak. For Swiss power and automation conglomerate ABB (NYSE:ABB), the weakness in mining, oil/gas, chemicals, and auto manufacturing is definitely a threat, and a call for stronger utility spending in the year ahead is definitely not a consensus call.

The good news is that it doesn't look as though ABB's management is just hiding under their desks and waiting for the storm to pass. Management has started up some relatively meaningful cost-cutting programs and is now examining whether they want to stay in the power grid business for the long term. Add in a healthy balance sheet that would facilitate M&A, and I think ABB is in okay shape heading into this downturn.

The shares are a trickier call right now. More often than not, buying into a downturn doesn't really work well. The exception is if and when the company in question manages to produce "less bad" performance than expected. I believe there's a chance for ABB to do that, and I do believe that these shares trade at a double-digit discount to fair value. That said, this company has earned some of the doubts around it concerning its margin leverage, its ability to spot and navigate industry downturns, and its ability to execute on value-additive M&A.

Continue here:
The Going's Getting Tougher - Will ABB Keep Going?

Seeking Alpha: BB&T Has A Full To-Do List For 2016

Back in July, I thought BB&T (NYSE:BBT) looked a little rich from a valuation perspective, and the shares have sold off about 5% since then - modestly underperforming peers like U.S. Bancorp (NYSE:USB), Wells Fargo (NYSE:WFC), PNC (NYSE:PNC), and Fifth Third (NASDAQ:FITB). Since that time, the company has increased its interest sensitivity a bit, announced another acquisition focused on Pennsylvania, and reiterated its commitment to grow by acquisitions while getting a little more conservative on overall loan growth.

Looking ahead, I don't think BB&T is done doing deals, but I don't believe the company is as likely to pull the trigger in 2016 unless a can't-miss opportunity comes along. Instead, I expect the company to prioritize the integration of its recent acquisitions and particularly the realization of expense synergies. At the same time, I would look for the company to try to offset pricing pressure in its insurance brokerage operations with greater volume and continue to develop its specialty lending operations.

I would describe BB&T's current valuation as "okay". The company paid up for its Pennsylvania acquisitions and its going to take time for those deals to show their value, putting even more pressure on those expense synergies. In the meantime, I like BB&T's strong credit quality and its disciplined approach to loan growth. Investors willing to take the elevated risk will find better banking bargains outside the U.S., but with a fair value in the low $40's, BB&T might be worth a look again today.

Read more here:
BB&T Has A Full To-Do List For 2016

Seeking Alpha: Lenovo Looking To Have The Last Seat When The Music Stops

It's easy to dismiss Lenovo (OTCPK:LNVGY) right now. What sane management team would want to be in the PC business when shipments are declining at a double-digit rate? What sane management company would want to battle high-end smartphone champion Apple (NASDAQ:AAPL) and low-end dynamo Xaomi with the rusty blade that is Motorola at their side? Why would anybody think there's money to be made in a server business that IBM (NYSE:IBM) didn't want?

What I think many of the superficial analyses of Lenovo miss is that this is a company with a proven ability to squeeze blood from a stone and relentlessly drive costs lower. While PCs are likely never going to be a growth market again, I do think there's still an opportunity for Lenovo to gain share and take what growth is there. Likewise, I don't think Lenovo ever unseats Apple in smartphones, but I believe Lenovo's cost structure can allow it to be one of the last companies standing after the industry shakes out the weaker players. Finally, I think there's meaningful server growth opportunity in China and other emerging markets, and here too I believe Lenovo has an opportunity to benefit from stripping costs out of the IBM assets and running the business more cost-effectively.

I've decided to take a more negative view of Lenovo's revenue growth prospects, as the decline in PC shipments has been exceeding my expectations from a year ago and the smartphone market too has cooled more quickly than I expected. Nevertheless, even with a lower revenue growth rate, the opportunity to add around a point and a half to operating margin over time and a similar amount to FCF margin supports a fair value above $28.

Lenovo has to achieve its cost-reduction goals for the Motorola business on schedule to rebuild investor/analyst trust, but I believe Lenovo has seen the bottom in mobile and servers and will surprise with what it does over the next three to five years. More importantly, I think Lenovo has a cost structure and a cost philosophy that makes it a long-term survivor - as virtually every market eventually becomes a commodity market over time, cost leadership is ultimately what distinguishes the survivors and I believe Lenovo has the corporate DNA to be the last (or at least one of the last) players standing in PCs, x86 servers, and phones.

Follow this link for more:
Lenovo Looking To Have The Last Seat When The Music Stops

Seeking Alpha: Does 3M Have Enough Cards Left To Play?

The current management team at 3M (NYSE:MMM) has done a lot to address the issues that used to contribute to the stock's historical relative undervaluation. Management has streamlined the company and boosted margins, maintained a strong internal R&D culture, continued to diversify geographically (particularly into faster-growing emerging markets), levered up to buy back shares, and gotten active on strategic M&A.

The market has noticed, and over CEO Inge Thulin's tenure the shares have outperformed the S&P 500 by about 15%. The shares have also outperformed peers/comps like General Electric (NYSE:GE) while keeping up with the likes of Honeywell (NYSE:HON), Danaher (NYSE:DHR), and Illinois Tool Works (NYSE:ITW).

The question I have, though, is whether 3M has enough cards left to play to continue that run of outperformance. Next year is looking pretty rough for the "general industrial" markets that make up a lot of 3M's business, not to mention the emerging markets that contributes to about one-third of the company's sales. Along similar lines, 3M doesn't have a lot of exposure to commercial aerospace or construction and I'm not sure there's too much left to accomplish on the restructuring side. Large M&A is still a possibility, but a transformative deal that moves the company into new markets would frankly be a little out of character.

Read the full article here:
Does 3M Have Enough Cards Left To Play?

Seeking Alpha: SK Telecom May Be Cheap For Some Good Reasons

I wasn't particularly bullish on SK Telecom (NYSE:SKM) back in April, but I thought the combination of more disciplined competition in the South Korean mobile market and increasing growth of LTE subs would at least be good for dividend coverage. As it turns out, growing MVNO subs and fierce rate competition have kept a lid on per-user growth, leading to several underwhelming quarters at the operating line. What's worse, it looks like management hasn't completely moved beyond its value destroying aspirations of empire building.

I guess the good news here is that the business hasn't eroded as dramatically as the 20%-plus decline in the share price might otherwise suggest. In fact, a lot of what's wrong with SK Telecom's share price performance could be tied to the wider rout in emerging markets, as the local shares (017670.KS) are down only about 8% more than the KOSPI index as a whole (-15% versus -7%).

The company's lower ARPU has led me to revise my growth expectations lower, but today's share price is still about 20% below my fair value estimate. Unfortunately, I have real concerns about management's ability to effectively deploy capital. Rumors of a spin-off of non-strategic investments in POSCO and Hynix are encouraging but not new, and I think investors considering these shares need to at least contemplate the risk that the shares look undervalued for some good reasons.

Read more here:
SK Telecom May Be Cheap For Some Good Reasons

Seeking Alpha: MTN Group Desperately Needs To Get Its Act Together

Emerging market stocks have had a bad year in general, with most of the diversified indexes showing double-digit losses. South Africa's MTN Group (OTCPK:MTNOY) has done substantially worse, falling more than 50% this year and doubling the poor performance of the iShares MSCI South Africa Index (NYSEARCA:EZA), as the company has faced competitive challenges in many African markets, ongoing executive turmoil, and a huge regulatory fine in Nigeria.

That the shares seem significantly undervalued and represent a diversified play on the growth of Africa is really the only reason to continue to put up with the drama and volatility. MTN Group does do some things right, and the company is seeing strong performance from mobile data and mobile money, but the company desperately needs to name a strong candidate as CEO and craft a plan that will see the company compete profitably in its markets.

I believe that mid single-digit long-term revenue growth and high single-digit FCF growth can support a fair value close to $14 for the ADRs. That represents a substantial erosion of value over past articles on this company, but the movement of the rand against the dollar (from around 10.50 to 15.20) has done a lot of the damage. Cooperatively resolving the fine in Nigeria, leveraging growth potential in Nigeria, Iran, and Ghana, and competing intelligently in South Africa would all help drive value apart from macroeconomic factors like currency rates.

Read more here:
MTN Group Desperately Needs To Get Its Act Together

Seeking Alpha: Turkcell Looking Long Term, Market Thinking Short Term

As a reader commented on a prior Turkcell (NYSE:TKC) piece, Turkey's leading mobile operator sits at the intersection of two unpopular avenues today - mobile communications and Turkey. Investors have grown impatient with the growth prospects of mobile carriers as penetration rates grow, revenue and earnings growth slows, and the capex bills grow to keep with the evolution of technology. On the Turkey side, there are no shortage of problems and concerns ranging from so-so economic growth (4% GDP in the third quarter), a high-profile spat with Russia that cost a pilot his life, and ongoing military conflict involving Daesh in Syria and the PKK in Turkey.

Turkcell's ADRs have lost about 20% of their value since early May of this year, with further adverse moves in the Turkish lira magnifying a double-digit decline in the home TCELL.IS shares. For the little to no good it does to make investors feel a little better, Vodafone's (NASDAQ:VOD) ADRs have declined about 10% and Turk Telecom's (OTC:TRKNF) local shares have fallen more than 25% in Turkey.

I realize that fighting the tape is an invitation to short-term pain, but I think the market is too worried about the near term at Turkcell and not willing to consider the long-term opportunities. Turkcell continues to gather higher value post-paid subscribers and has been generating good growth from its mobile data, and the company's substantial investments in spectrum will have the company positioned for mobile data leadership for a decade. Turkcell's ADRs definitely need a more favorable outlook/sentiment for Turkey as a whole, but with a fair value close to $12, I think these shares are worth a look from patient investors today.

Please click here for more:
Turkcell Looking Long Term, Market Thinking Short Term

Seeking Alpha: Multi-Color Trading Short-Term Pain For Long-Term Gain

I've had my issues with the valuation of Multi-Color (NASDAQ:LABL) from time to time, but I can't really complain about the overall performance of this "under-known" label company, as the shares are up over 200% for me as an investor and up about 150% from my first article on the company for Seeking Alpha. While management still has work to do on gross margin improvement, the company has delivered operating margin improvements while using M&A to grow its revenue base and establish foothold in growth markets.

Although the label industry isn't really R&D-driven, Multi-Color doesn't really get its due for innovation in areas like in-mold and heat-transfer labels, nor value-added features like peel-aways, holographics, tamper resistance, and other technically demanding innovations. I also wonder if the Street appreciates that about half of the company's plants are still operating below management's long-term margin targets and could offer significant margin leverage in the coming years.

To be sure, I'm not saying that Multi-Color is a cheap stock. I might still be too conservative with my numbers, but I think 10% free cash flow margins are still at least five years away (on a sustainable basis). The shares do trade at an EV/EBITDA multiple below my expected EBITDA growth rate, but this is a stock that I'd be a lot more aggressive on below $60.

Read the full article here:
Multi-Color Trading Short-Term Pain For Long-Term Gain

Seeking Alpha: After Multiple Updates, Alnylam Hasn't Cleared Up Much

It's hard to say that Alnylam (NASDAQ:ALNY) has been badly treated by the market when it still sports a $7.5 billion market cap with no approved drugs (and no approvals likely until 2018). Leaving aside the impact of the debate about drug pricing and the overall turbulence of the biotech sector, there have been some Alynylam-specific issues weighing on investors' minds - including the efficacy and tolerability of revusiran and the efficacy of fitusiran and ALN-CC5.

The latter, in particular, seems to be a flashpoint with investors, as some bulls had hoped this would be a "Soliris-killer" and an heir to the substantial revenue that Alexion (NASDAQ:ALXN) has generated in complement-mediated diseases like paroxysmal nocturnal hemoglobnuria (or PHN). Unfortunately, data presented at the ASH meeting and further discussed at the company's R&D day haven't really improved the sentiment.

As ALN-CC5 is not a big part of my valuation for Alnylam, I'm not bothered by the implications that it is not a clear winner in complemented-mediated diseases. Moreover, I think Alnylam has a potential winner in hemophilia and a deep overall pipeline of RNA interference drugs that will generate stock-moving clinical data in 2016.

Continue here for more:
After Multiple Updates, Alnylam Hasn't Cleared Up Much

Seeking Alpha: PRA Group Feeling A Tough Squeeze

Whatever the arguments about PRA Group's (NASDAQ:PRAA) underlying financial performance, there is really no argument that the stock market performance has been abysmal, with the shares down almost 40% since my last update on the company. PRA Group is trying to deal with multiple headwinds at once - the bankruptcy business has fallen off sharply, regulatory impediments are increasing, supply is tight, and the company is no longer in a part of the cycle that is as conducive to attractive collections numbers.

PRAA has navigated cyclical ups and downs before, and I believe the company will do so successfully once again. It's a high-risk call, though, as the company can do little to influence supply or the regulatory environment and the company's size makes outperformance more challenging. I believe the market is assuming a pretty sharp drop in the long-term profitability of the business that doesn't fully account for the potential of the non-U.S. business, nor the money to be made when large traditional sellers return to the market. Given the challenging accounting here and the generally reviled nature of the debt collection industry, I believe this is a story with high risk to offset the significant potential gains if 20% ROEs are still in play on a long-term basis.

Click here for more:
PRA Group Feeling A Tough Squeeze

Seeking Alpha: Maxwell's Road Still Bumpy, But Seems To Be Leading Somewhere

Maxwell (NASDAQ:MXWL) continues to be an exasperating story. On one hand, it's one of the only real ultracapacitor companies out there (let alone one of the only investable ones) and the company has scored wins with legitimate companies like Continental AG (OTCPK:CTTAY) and PACCAR (NASDAQ:PCAR). On the other hand, the company's excessive reliance on the heavily-subsidized Chinese bus and wind power markets has created a lot of volatility and left it exposed to intense price competition.

There is a very real chance that Maxwell could log three straight years of revenue contraction before seeing growth again in 2017, and that's hardly consistent with a traditional growth story. On the other hand, truck and passenger car manufacturers do seem to be increasingly interested in Maxwell's ultracapacitor technology and these two markets could drive meaningful future growth. A potentially sharp downturn in the Chinese bus opportunity over the next couple of years leads me to cut my fair value slightly and I'm not sure there's enough upside today to be worth the risk, but management's efforts to simultaneously sign up new OEM customers and improve margins could start paying off significantly in a couple of years.

Read the full article here:
Maxwell's Road Still Bumpy, But Seems To Be Leading Somewhere

Seeking Alpha: From Bad To Worse For MSC Industrial's Core Markets

I had my concerns about MSC Industrial (NYSE:MSM) back in the summer, as I was worried that ongoing weakness in U.S. manufacturing would make it harder for the company to achieve its margin leverage goals and grow revenue. That's proven to be the case, with monthly sales having turned negative and the shares losing another 22% or so in value from that last article.

I still believe that MSC Industrial is a good house in an increasingly sketchy neighborhood, and that's a tricky set-up for investors. Investors looking for more short-term punch (and/or who can't stand seeing near-term losses) should avoid these shares until there are real signs of strength in durable goods orders, ISM's purchasing managers' index, and other manufacturing metrics. More patient value-oriented investors may want to take a closer look, though, as there could be meaningful margin leverage and share gains pushing results (and the share price) higher over the long term.

Read more here:
From Bad To Worse For MSC Industrial's Core Markets

Seeking Alpha: Decision Time With Broadcom ... And Maybe With The Larger Sector

As the transaction with Avago (NASDAQ:AVGO) moves forward, Broadcom (NASDAQ:BRCM) investors have to make their decision on what to do with their shares. While shareholders may not ultimately get exactly what they want (the deal is subject to proration), they have the option to take cash, regular shares, or special restricted shares.

Investors are also looking at a changing semiconductor landscape. Barring any additional announcements before year-end, 2015 has already seen more than 25% of U.S. publicly-listed semiconductor stocks acquired or underway with being acquired. Given the rising cost of chip development, the low cost of debt and high cash balances at chip companies, and the opportunity to drive synergies, there may be more decisions like the Broadcom situation coming for investors.

Read more here:
Decision Time With Broadcom ... And Maybe With The Larger Sector

Personal update

I'm not sure how many people come here (and only here) for articles and updates vs. Seeking Alpha, so I thought I'd offer a quick update on my wife's condition. Between Facebook, Seeking Alpha, and personal emails, I'm not really able to remember where I've said what, so apologies if there repetitions here.

This past week my wife ended her second round of radiation and received another pembro infusion. The radiation was a five-day course intended to treat a metastatic tumor in her pelvis that has caused her muscle pain and some loss of mobility. While she hasn't experienced the severe pain you often hear about with bone mets, it was enough to cause her to need ibuprofen every day and eventually need a cane to walk. Interestingly, ibuprofen is a more effective pain reliever for bony mets than heavier painkillers (like oxy).

Anyways, we should know relatively soon whether the radiation helped. The oncologist was not optimistic that it would cure that tumor or be a 100% solution, but it should help.

On the chemo front, her bloodwork has stayed quite good, which is very positive. It doesn't prove that her liver tumors are quiet, but it does suggest they're not causing significant damage to the liver at this point. We'll know more in February when she gets her next CT/PET. For the time being, though, she's doing pretty well - the drug seems to be keeping the cancer in check and is not causing too many side-effects. The most curious side-effect is that it seems to intensify muscle aches/pains. It doesn't cause them, but if she has them around the time of the infusion, the drug seems to dial them up.

So, that's about it. She is feeling pretty well, and that's about the best we can expect for now.

Seeking Alpha: Orchids Paper Products Continues To Blossom

It's always encouraging to see stories develop in line with your expectations, and I really have nothing to complain about when it comes to Orchids Paper Products (NYSEMKT:TIS). The shares are up about 30% from April, when I wrote that the company's strategy of "controlled aggression" toward geographic expansion and its cost consciousness could serve investors well as a GARP story.

The story here continues to center around the growth potential of private label tissue products, the company's geographic expansion, and management's prudent approach to costs. Valuation is a more interesting topic to me though, as I think an argument can be made that a FCF-based target in the high $30s is not unreasonable. While that works back to a 10x multiple on 2016 EBITDA, a high multiple for a paper company, it might not be so unreasonable relative to the three-to-five year growth potential.

Read more here:
Orchids Paper Products Continues To Blossom

Seeking Alpha: Pacific Biosciences Has Taken Some Big Steps Forward

It has been a while since I've written about next-gen sequencing company Pacific Biosciences (NASDAQ:PACB), but this is definitely a case where absence has made the heart grow fonder. The shares are up more than 75% from that last piece in March of this year, and up a solid 260% from my June 2013 Top Idea call.

What has changed? Well, for starters, PacBio has done a very good job of addressing the prior shortcomings (both real and perceived) of its technology, rolling out a series of improvements that have made the system more useful and economical for researchers. That has, in turn, supported management's goal of significant improvements in system utilization as measured by consumable sales relative to the installed base. The company also scored a significant deal with Roche (OTCQX:RHHBY), a major player in clinical diagnostics, to develop a platform suitable for human in vitro diagnostics.

More recently, PacBio launched a new platform called Sequel. The underlying technology has remained the same, but the company now offers a smaller, cheaper machine with a significantly improved throughput. While PacBio is never going to threaten Illumina (NASDAQ:ILMN) for rulership in next-gen sequencing, PacBio has strengthened its case that it has a very particular set of skills that ought not be underestimated.

I believe Sequel can take PacBio to a new level of system placement, utilization, and revenue, but then so too does the market. I had already expected a lot from this company and while there have been some aspects of outperformance, my refreshed fair value range of $10 to $11 doesn't leave huge obvious upside. I may yet be underestimating PacBio, but this currently looks more like a "consider on a pullback" opportunity than a "buy it all you can today" situation.

Read more here:
Pacific Biosciences Has Taken Some Big Steps Forward

Seeking Alpha: Ultratech's Convoluted And Uncertain Path

The Ultratech (NASDAQ:UTEK) story continues to be an exercise in frustration. While management has long argued that its laser annealing technology was the superior option for sub-20nm chip fabs, the reality is that fabs like Taiwan Semiconductor (NYSE:TSM) and Samsung (OTC:SSNLF) just aren't all that dismayed by the issues with the flash annealing tools offered by rivals like Screen Holdings (OTC:DINRY) and Mattson (NASDAQ:MTSN). With that, the argument that LSA tools would replicate their 50%-plus share of 28nm manufacturing at 14nm/16nm has evaporated, and the real market share has been closer to the 20% seen at the 45nm node.

Looking at this a different way, what was supposed to be a year of momentum in LSA tool orders and roughly $200 million in revenue (the sell-side expectation in December of 2014) has instead turned into minimal order activity (none in the third quarter) and probably something closer to $150 million to $160 million in 2015 revenue.

What to do with these shares now? The shares are actually up about 10% from my last update and now arguably (very arguably, in my opinion) have a new value metric established by the merger agreement that Mattson signed with Beijing E-Town Dragon Semiconductor. What's more, I do think there is legitimate momentum in the advanced packaging (AP) business and good prospects in metrology. On the other hand, I just don't have the confidence in management that I once did, and I think Ultratech is firmly in the "show me" penalty box today.

Read more here:
Ultratech's Convoluted And Uncertain Path

Seeking Alpha: BRF Sticking To Its Plan In A Challenging Market

The ever-volatile, and generally bad, economic situation in Brazil isn't doing any favors for BRF S.A. (NYSE:BRFS), and neither is increasing competition. Worries about market share and a potential price war in Brazil cast an already tough third quarter in an even more negative light, helping accelerate a nearly 20% decline in the Brazilian shares since my August update and a nearly 30% decline in the ADRs.

As I have warned in prior pieces, BRF shares and ADRs have always been more volatile than global integrated food companies like Nestle (OTCPK:NSRGY) and General Mills (NYSE:GIS) and I expect that to be the case for the foreseeable future. Nevertheless, I think fears of a price war are overdone and I believe BRF's management continues to execute on a very sound plan to position the company as a truly global protein and processed foods player.

Absent a more robust recovery in Brazil (which nobody seems to expect right now), it's going to likely take a couple of strong quarters for BRF to get back into investors' good graces. Unfortunately, growing poultry export competition from U.S. producers, higher grain prices, and a tougher domestic market could make that a more prolonged process than investors would like to see. I still believe BRF shares are an attractive long-term holding, and that this is the sort of pullback that investors can/should use to build positions, but the next quarter or two could offer a level of volatility that nervous investors won't like.

Continue here:
BRF Sticking To Its Plan In A Challenging Market

Seeking Alpha: In A Bad Ag Market, Can Monsanto Do Enough That Matters?

Monsanto (NYSE:MON) wasn't the first to feel the pinch from the negative ag cycle, and it certainly hasn't suffered the most, but weak grain prices have nevertheless done their damage. Monsanto's shares are down about 10% from my last update, and about 20% over the last year, as investor expectations and analyst targets have dropped significantly in the face of weak crop pricing and pinched farmer budgets.

There's always a big "but" that goes with forecasting the results for any ag-sensitive company and that is the unpredictability of the underlying market; a really bad (or good) crop could shift prices dramatically and change MON's operating environment quickly. That said, a lot of those fluctuations even out over time, and I believe the company's deep, high-quality R&D operation is a strong source of future value.

My expectations for Monsanto were lower than the Street's prior to this most recent reckoning, so my revisions are correspondingly more mild. I still expect MON to be a 10%-plus long-term grower, supporting a $105 fair value today and maybe some upside if a deal for Syngenta (NYSE:SYT) or another strategic target materializes.

Continue reading here:
In A Bad Ag Market, Can Monsanto Do Enough That Matters?

Seeking Alpha: Societe Generale Not Getting Its Due

It's been a disappointing summer and fall for European bank stocks, and despite two solid quarters with double-digit earnings beats, Societe Generale (OTCPK:SCGLY) (GLE.FR) has been unable to beat that trend in European bank stocks. While the shares haven't done as badly as names like Credit Agricole (OTCPK:CRARY) (down about 24%), Banco Bilbao (NYSE:BBVA) (down about 25%), or UniCredit (OTCPK:UNCFF) (down 20%), SocGen is still down about 6% from my last update.

I believe this performance has created a more interesting gap between the bank's current price and long-term potential. The world has certainly changed for large banks, and the higher capital levels that regulators are demanding will make it much harder (if not impossible) to achieve past high-water marks in ROE/ROTE/ROA. What's more, I wouldn't say that Western Europe is quite the picture of economic health yet, and Russia still has the potential to get worse before it gets any better. All of that said, I think SocGen has made underrated progress with its French retail operations, its retail operations outside of France, and with its overall costs and capital allocation. I believe that fair value for the ADRs is around $11.50 to $12.50, making these shares a more interesting consideration particularly when including the dividend.

Read more here:
Societe Generale Not Getting Its Due

Seeking Alpha: Wright Medical Has To Execute Against A Promising Backdrop

It's been a busy few months for Wright Medical (NASDAQ:WMGI). The company completed its merger with Tornier, creating a new entity with a strong share in the fast-growing orthopedic extremities sub-sector. Wright Medical also managed to secure FDA approval for its long-awaited Augment biological, a product that could be game changer with multi-hundred million dollar sales potential.

Now comes the harder, and decidedly less glamorous, part - execution. Wright Medical will have to deal with Johnson & Johnson (NYSE:JNJ), Stryker (NYSE:SYK), and Zimmer Biomet (NYSE:ZBH) on a daily basis, while also integrating the sales forces and ensuring a smooth transition into a blended entity. The high-single digit market growth of upper and lower extremities makes this a potentially strong multi-year growth story, but Wall Street won't be forgiving if the sales growth and cost synergies don't materialize.

Read more here:
Wright Medical Has To Execute Against A Promising Backdrop

Seeking Alpha: Improving Traffic And Aggressive Capital Deployment Makes FEMSA An Intriguing Story

I can't complain about FEMSA's (NYSE:FMX) performance since my last write-up, as the U.S. ADRs of this leading Mexican retailer have risen more than 10%. Better still, the company's underlying financial performance has been pretty solid, and management has continued to deploy capital to support the long-term growth of the business.

I really like the company's expansion into Chile's drugstore sector, and I fully expect that FEMSA will follow it up with an expansion of its OXXO C-store concept into this under-penetrated country. I also expect further consolidation of the Mexican drugstore market, and I wouldn't be surprised if Coca-Cola FEMSA (NYSE:KOF) looks at a deal or two of its own. There is also the question of what FEMSA's management may elect to do with its Heineken (OTCQX:HEINY)(OTCQX:HKHHY) stake now that the lockup has expired and an acquisition of Heineken by SABMiller (OTCPK:SBMRY) is clearly off the table.

The "but" is that the move in the shares has mopped up a chunk of the undervaluation I saw back in the summer. I still like FEMSA as a long-term holding as I believe the company is on a trajectory to become one of, if not the, largest retailers south of the U.S. border over time. At this point, though, I would be inclined to advise new investors to hold off on building a full position in the hope that a market pullback would greater a bigger discount to full value.

Read the full article here:
Improving Traffic And Aggressive Capital Deployment Makes FEMSA An Intriguing Story

Seeking Alpha: Commercial Vehicle Changing Gears At An Inopportune Time

As a turnaround story, Commercial Vehicle Group (NASDAQ:CVGI) has been a lousy call. The company has not had all that much success growing share within the seating market for commercial trucks, and management has tried to build up it agriculture and construction businesses during major downturns in those two markets. While the company has made what I consider to be underrated progress in improving its margins, balance sheet, and free cash flow, the fact remains that the shares are down almost 50% over the past year and about 60% over the past three years - significantly underperforming other commercial vehicle parts/components manufacturers like Cummins (NYSE:CMI), Allison (NYSE:ALSN), and Grammer AG.

Now things are about to get even more challenging. The North American commercial truck market is likely at or near its near-term peak, and that doesn't bode well for volumes, or margins, in the company's largest and most profitable business. The ag and construction markets are still soft and not really in a position to contribute offsetting growth. Last and by no means least, the company recently announced the departure of its CEO after less than three years in the job.

While the shares arguably do still trade below fair value, it's hard to argue that investors need to risk their hard-earned money on this turnaround story. The company could well be looking at two or three years of revenue contraction and margin deleverage, and that is often enough to scare off most investors. Patience could still pay here, but the ride is likely to get a lot bumpier before smoothing out.

Follow this link for more:
Commercial Vehicle Changing Gears At An Inopportune Time

Seeking Alpha: Old Dominion's Operating Environment Has Shifted

Maybe the nicest thing I can say about Old Dominion's (NASDAQ:ODFL) performance since my last update on this leading less-than-truckload carrier is that even in a rough patch for trucking, the company has continued to do better than most of its peers. The shares are down about 20% over the past nine months, but ArcBest (NASDAQ:ARCB), Saia (NASDAQ:SAIA), and Roadrunner (NYSE:RRTS) have all done notably worse, with YRC Worldwide (NASDAQ:YRCW) the only notable outperformer excluding M&A.

My prior positive view on Old Dominion was predicated on a healthy economy and continuing excellence in operation, and only the second of those has really materialized. I continue to believe it is the best-run trucking company out there (at least in the LTL space), but a softer industrial economy, reduced truckload spillover, and changing shipping patterns are creating notable headwinds. Although I believe the shares are trading at an interesting valuation today, the Street will likely want to see weight trends and economic activity improve before getting significantly more bullish.

Continue reading here:
Old Dominion's Operating Environment Has Shifted

Seeking Alpha: Air Transport Services Group Ready To Take Off

I liked the direction of Air Transport Services Group (NASDAQ:ATSG) back in April, as the company had taken steps to reduce some of the contract risks with its huge DHL business, was building business with the likes of Cargojet (OTC:CGJTF) and West Atlantic, and was about to begin repurchasing shares. What I didn't like so much was the valuation, and with the shares basically flat since then (up 2% against a 1% decline in the S&P 500), I don't feel like I've missed out on all that much.

There are some legitimate areas of concern in the global airfreight market. Airfreight volumes are up for the year, but have been outpaced by capacity growth and it's hard to find much optimism regarding the health of the U.S. or Chinese economies. That said, Air Transport's regional focus is an important differentiator, as it gives the company exposure to e-commerce growth, and the company's efforts to diversify its business seem to be on a good track. I wish my fair values weren't so closely aligned with the sell-side consensus, but I do think fair value for these shares lies between $11 and $12 today and supports an interesting value opportunity.

Read more here:
Air Transport Services Group Ready To Take Off

Seeking Alpha: Kirby Tossed By The Crude Market

Persistently weak oil prices have continued to apply pressure to Kirby's (NYSE:KEX) valuation, as the shares are down more than 10% from my last update on this leading operator of tank barges. While Kirby's direct exposure to crude oil is relatively modest, the company can't escape the downstream consequences of less demand for crude oil transportation or the worries around a broader economic slowdown in the U.S. that would impact its petrochemical business.

Over the long term, Kirby should be fine. The large number of chemical plant expansions and newbuilds already underway should support future demand for inland barges, and the eventual expansion of domestic crude production should help both the inland and coastal businesses.

The question is how long "over the long term" takes to materialize. Pricing has softened in the inland business (with contracts renewing at prices down by the low-single digits) and there are plenty of examples of businesses/industries that have seen cyclical pullbacks go longer and deeper than expected. Kirby looks undervalued relative to its historical EV/EBITDA averages, but with three straight guidance cuts, it is hard to argue that the business has stabilized or found its bottom yet.

Continue here:
Kirby Tossed By The Crude Market

Seeking Alpha: China's Economic Challenges Making Life More Difficult For HollySys

As a company that generates the lion's share of its revenue and profits from capital spending in China, the last year has not been an easy one for HollySys (NASDAQ:HOLI) (also sometimes written as "Hollysys"). Like Siemens (SI) (OTCPK:SIEGY), Rockwell (NYSE:ROK), ABB (NYSE:ABB), and the rest of the factory and process automation sector, HollySys has seen a sharp correction in demand for automation systems. While the rail system business has offset this to some extent, here too orders have been inconsistent.

It's difficult to strongly recommend a stock that is so heavily exposed to capital spending in China at a time when China's economic outlook is still murky at best. Patient value investors will argue that that's the time you want to go shopping, and while I agree with that sentiment, the reality is that investors considering HollySys's shares need to brace themselves for the possibility that the business hasn't yet bottomed and that there could be downside risk ahead of a recovery. I still believe that this company can be a high-single-digit grower over time, though, and the stock should trade closer to the mid-$20s.

Continue here:
China's Economic Challenges Making Life More Difficult For HollySys

Seeking Alpha: Roche Could Be A Victim Of Its Own Success

Roche (OTCQX:RHHBY) (ROG.VX) hasn't done all that well in the market of late, with the shares down about 6% over the past year. Then again, that's not so bad in the larger context - Pfizer (NYSE:PFE) and Bristol-Myers (NYSE:BMY) have done significantly better (both up about 11%), but Novartis (NYSE:NVS), Merck (NYSE:MRK), and AstraZeneca (NYSE:AZN) have performed just as poorly or worse than Roche.

This market performance forms an interesting contrast with the news that Roche has been reporting. The company continues to advance one of the deepest oncology/immuno-oncology portfolios, and the company's efforts outside of cancer have achieved some notable successes of late in hemophilia and multiple sclerosis.

Even so, the question remains as to whether this will be enough to push the company back to double-digit earnings growth. Not only are politicians taking a harsher tone on drug pricing, but Roche faces significant challenges from biosimilars and intense competition in oncology. I continue to believe that Roche is a high-quality, well-run drug company, but Roche's success not only makes it a prime target for its competition but also makes it harder for the next generation of blockbusters to do more than simply maintain what the company already has.

Read more here:
Roche Could Be A Victim Of Its Own Success

Seeking Alpha: Alnylam Pharmaceuticals Keeping Multiple High-Potential Programs Moving Forward

The biotech sector has gotten a little "interesting" since drug pricing re-emerged as a tempting target for political soundbites and investors started looking back on just how far the sector has come in terms of valuation and multiples. Alnylam Pharmaceuticals (NASDAQ:ALNY) has taken its share of drubbing, with the shares down about 20% since my last piece on concerns about the implications of potential drug pricing reforms on its largely orphan drug-focused pipeline, as well as concerns relating to the company's Phase III revusiran program.

I wasn't thrilled with the valuation back in June, but I think the combination of the share price performance and the company's clinical updates makes for a more interesting opportunity today. Time will tell whether my estimates and model are reasonable, conservative, or aggressive, but I do see significant value-add potential over the next six months as more information comes out on programs like ALN-CC5, ALN-AT3, ALN-GO1, and the core TTR platform.

Click here for the full article:
Alnylam Pharmaceuticals Keeping Multiple High-Potential Programs Moving Forward

Seeking Alpha: Steady, Albeit Not Spectacular, Progress At Accuray

Patience may be a moral virtue, but it's not a particularly compelling investment thesis. To that end, Accuray (NASDAQ:ARAY) is most definitely making progress from an operational standpoint, and is operationally outperforming its much larger rivals Varian (NYSE:VAR) and Elekta (OTCPK:EKTAY), but the pace of the progress is likely stifling the enthusiasm of would-be new investors.

I continue to hold Accuray as a small position in my portfolio because I think the company has turned the corner and remains meaningfully undervalued. Not only has the company improved its Tomo platform to a point where it is a legitimate standalone option, but the company's CyberKnife system is well positioned to take advantage of growing adoption of stereotactic radiosurgery and stereotactic body radiation therapy. With a fair value range of $9 to $12, there is still meaningful upside if, or when, investors become more comfortable that the company is establishing a more consistent pace of order and revenue growth and a credible road to profits and free cash flow.

Read the full article here:
Steady, Albeit Not Spectacular, Progress At Accuray

Seeking Alpha: Is Microsemi Courting The Winner's Curse?

I've written pretty regularly on Microsemi (NASDAQ:MSCC) for Seeking Alpha, and this has long been a semiconductor stock that I've liked (and own in my own portfolio). Along the way, I've often mentioned that additional M&A felt like a "when, not if" question given Microsemi's past success in using deals to broaden its product, market, and technology exposures. I wasn't expecting something quite as dramatic as the company's bid for PMC-Sierra (NASDAQ:PMCS), but this is a deal that otherwise fits Microsemi's pattern of diversification, cost synergy, and market expansion.

I believe that PMC-Sierra can be a good deal for Microsemi, but I openly acknowledge that Skyworks (NASDAQ:SWKS) will prevail in the end if that company decides that it simply cannot afford to let PMC-Sierra slip away. I also believe, though, that Microsemi has more to gain in terms of synergies and market diversification. Last and not least, while Skyworks' all-cash deal is definitely a lower-risk proposal for PMC-Sierra shareholders, Microsemi's offer appears to me to give PMC-Sierra shareholders more long-term upside.

Continue here:
Is Microsemi Courting The Winner's Curse?

Seeking Alpha: Neurocrine Biosciences Has The Flash And The Cash

It wasn't all that long ago that I last updated my thoughts on Neurocrine Biosciences (NASDAQ:NBIX), but the company has made a few noteworthy moves since then that are worth mentioning. Neurocrine remains a very promising biotech on multiple levels. First, the company has two late-stage compounds that each have more than $1 billion in revenue potential. Second, the company has recently shown that it can, in fact, add new compounds to its pipeline. Third, the company has quite a bit of cash on hand, ending the last quarter with nearly half a billion dollars. Last and not least, there remain multiple upcoming events that can attract attention and drive positive sentiment.

The "but" is valuation. It's hard to recommend any development-stage biotech unless the potential gains are such that it's worth overlooking the industry's generally poor track record (most biotechs never develop a commercial product). I do think that Neurocrine is undervalued, and my underlying assumptions may prove conservative, but investors may want to hope for another biotech sector freakout that could push the price down 20% or more.

Read more here:
Neurocrine Biosciences Has The Flash And The Cash

Seeking Alpha: Plum Creek's Value Finally Realized, But Weyerhaeuser Has Some Work To Do

I've been relatively bullish on Plum Creek Timber (NYSE:PCL) for a while, arguing (maybe stubbornly) that the shares were valued too cheaply in the public market relative to private market timberland transactions and the potential cash flow and value to be realized from timber and land sales as the U.S. housing market recovers.

It would seem that Weyerhaeuser (NYSE:WY) had at least a somewhat similar view of the situation, as the two companies have announced a merger that will see the two companies merge in an all-stock deal that will leave Weyerhaeuser shareholders with 65% of the combined company. Together, these two companies will own over 13 million acres of timberland, offering even more exposure to a housing recovery but also creating an opportunity for Weyerhaeuser to drive more value from Plum Creek's assets.

Follow this link for more:
Plum Creek's Value Finally Realized, But Weyerhaeuser Has Some Work To Do

Seeking Alpha: Lundbeck Executing Where It Can, But The Biggest Drivers Are Risky

As I've written in the past, I think being a little reluctant to sell out of a good position is far from the worst trait an investor could have. To that end, while I saw less value left in the shares of Danish drug company H. Lundbeck (OTCPK:HLUYY) (LUN.CO) than I would have liked back in August, I was hesitant to sell ahead of potential upside in the cost-cutting program.

Since that last article, Lundbeck shares have logged solid double-digit appreciation and outperformed most pharmaceutical peers. Moreover, the company has provided some evidence that the cost-cutting efforts will drive better profit improvements than the sell-side initially expected. That said, the valuation argument is even harder to make now, and the prime drivers of further outperformance are both risky and at least a few months off.

Read more here:
Lundbeck Executing Where It Can, But The Biggest Drivers Are Risky

Seeking Alpha: Lexicon Pharmaceuticals Produces Another Positive Surprise

This has been quite the year for Lexicon Pharmaceuticals (NASDAQ:LXRX), as long-suffering shareholders have finally seen the stock do well on the back of optimism about the company's oral treatment (telotristat etiprate) for the GI effects of carcinoid syndrome and its progress into Phase III testing of its SGLT-1/SGLT-2 inhibitor sotagliflozin for Type 1 diabetes. Now the company has achieved a more surprising success, with Friday's announcement of a partnership with diabetes giant Sanofi (NYSE:SNY) to develop and commercialize sotagliflozin for both Type 1 and Type 2 diabetes.

Lexicon investors (or at least most of them) had pretty much written off the chance of a major partnership more than a year ago, as the company had been shopping the drug to partners for about two years without reaching any sort of agreement. Now, though, the $1 billion-plus potential of sotagliflozin in Type 2 diabetes is at least back on the table as a point of discussion.

There are still plenty of unknowns here to confound valuation. What sort of pricing will the company get for telotristat etiprate? Will it become the go-to choice for patients getting inadequate relief from somatostatin analogs? Does Sanofi have the marketing muscle to drive meaningful market share with a drug that will be quite late to market? Will sotagliflozin show any distinctive efficacy or safety aspects in large-scale studies (good or bad) that will impact its market potential? Will the company choose to rejuvenate its internal drug development programs? These are all important questions, but I would nevertheless argue that Lexicon remains meaningfully undervalued today.

Read more here:
Lexicon Pharmaceuticals Produces Another Positive Surprise

Seeking Alpha: The Market Is Skeptical Toward ON Semiconductor ... As It Should Be

"Under-promise and over-deliver" is popular corporate speak, but apparently not a central part of the operating philosophy at ON Semiconductor (NASDAQ:ON). Although I do think that ON Semiconductor has some good things going for it and has done a respectable job of improving its cost structure, there has been a trend in place here for some time of promising more than is actually delivered.

That's an admittedly harsh opening statement on a company that, on balance, I still like. I wasn't all that fond of the shares back in March (and the price has fallen about 20% since), but the stock's performance relative to Texas Instruments (NASDAQ:TXN), Maxim (NASDAQ:MXIM), and Fairchild (NASDAQ:FCS) hasn't been too bad over the last year (or three years), though NXP (NASDAQ:NXPI) has handily outperformed the group. With this pullback, I think the shares are once again a more interesting prospect, particularly given growth opportunities in wireless, computing, and autos, but for as much as the performance of these shares may be tied to future revenue growth and margin improvements, a stronger sense of credibility from management may be the biggest potential catalyst of all.

Continue here:
The Market Is Skeptical Toward ON Semiconductor ... As It Should Be

Brief apology on posting

I want to apologize to folks who depend on my posts here to keep up with my work - I've obviously forgotten to post some articles in a timely fashion. I'm happy to say that there's no "bad news reason" for this, and instead it's just a byproduct of being a little busy and sometimes forgetting to do it at night.

On a related note, I probably won't be writing as much this coming week (even though its earnings season), as my wife has multiple appointments and it's tough for me to "get in the groove" for a half-day or less of writing. But here's hoping the bloodwork and next infusion go smoothly on Wednesday!

Seeking Alpha: Neurocrine Biosciences Racks Up Some Much-Needed Good News

Stock prices in the biotech sector are getting carpet-bombed as investors bail out of the sector, but this is still fundamentally a data-driven industry where good data almost always win out in the end. To that end, Neurocrine Biosciences' (NASDAQ:NBIX) recent run of good news should encourage shareholders even as the market has turned cold on these once-outperforming shares.

Neurocrine Biosciences remains a challenging biotech to value, due in part to the fact that the markets that the company's lead drugs are targeting could prove to be substantially more robust than they seem at present. Even with what I believe to be relatively conservative assumptions, though, Neurocrine's shares look appealingly undervalued.

Click here for more:
Neurocrine Biosciences Racks Up Some Much-Needed Good News

Seeking Alpha: AGT Food And Ingredients Still Offers Interesting Upside

Canada's AGT Food and Ingredients (AGT.TO)/(OTCPK:AGXXF) has two characteristics that I really like in a publicly traded company - it does something that most investors find mind-numbingly tedious (sorting and processing pulses) and it is shifting its business up the value chain. I can't say that these efforts have gone unnoticed, as the shares are up about 7% since my last article and up 78% since my first article on the company for Seeking Alpha, but I believe the company's leadership position in pulse processing and nascent efforts in food ingredients can generate enough cash flow growth to make these shares interesting on a long-term basis.

Read the full article here:
AGT Food And Ingredients Still Offers Interesting Upside

Seeking Alpha: Core-Mark Continues To Deliver With A Plan That Can Drive Further Growth

While I had some concerns about Core-Mark's (NASDAQ:CORE) valuation back in March, and there was a noticeable pullback in April that lingered for a few months. The shares have fought back to just above break-even for the year as this large convenience store (or "C-store") distributor continues to deliver good same-store sales growth and EBITDA leverage.

My concerns about the valuation are still in place, but I do still see opportunities for Core-Mark to outperform in terms of customer acquisition (competitive wins and M&A), improved infrastructure utilization, and greater penetration of value-added services. Were the shares to offer up another 10%-plus pullback, I would certainly be more interested, but this at least looks like a credible hold for now.

Continue here:
Core-Mark Continues To Deliver With A Plan That Can Drive Further Growth

Seeking Alpha: Coloplast Is A Rare Story On Multiple Levels

You don't see many large-cap med-tech stocks trade for more than seven times sales, but then you don't see many companies in that space logging high-single digit sales growth and excellent margins/returns on capital with a significant opportunity to grow sales and profits even further. That's the basic story on Coloplast (OTCPK:CLPBY) - a Danish med-tech company that has built an excellent business by focusing on some decidedly un-sexy areas of healthcare like ostomy and incontinence - and it creates a challenge for investors. While investors can do well in supposedly "boring" med-tech stories like Becton Dickinson (NYSE:BDX) and Bard (NYSE:BCR), it's tough to ignore an eye-watering multiple even when the growth is strong.

Read the full article here:
Coloplast Is A Rare Story On Multiple Levels

Seeking Alpha: LDR Holding Corp. Seems To Be In The Right Place At The Right Time

The spinal surgery/spinal care market has been marked in recent years by a few trends that run counter to how many investors historically see the med-tech market. First, size hasn't proven to be such an insurmountable competitive advantage, as up-and-comers like NuVasive (NASDAQ:NUVA), LDR Holding (NASDAQ:LDRH), and Globus (NYSE:GMED) have gained share at the expense of larger rivals like Johnson & Johnson (NYSE:JNJ) and Medtronic (NYSE:MDT). Second, and apologies for the obvious pun, it seems to be one of the few areas of medicine where insurers have found some backbone and pushed back on pricing.

The subject of this article, LDR Holding, strikes me as an appealing growth story in med-tech by virtue of its commitment to doing things differently in the spinal space. Not only does the company have a strong product in the fast-growing cervical disc replacement market, but the company is also advancing technology in the lumbar area that features less hardware and less collateral damage to the patient. LDR Holding still has a difficult climb on its way to the top, including not only competition with the likes of JNJ and Medtronic, but also surgeon inertia, and the valuation is not obviously cheap, but the balance between growth and valuation is at least promising enough to look closer.

Click here for the full article:
LDR Holding Corp. Seems To Be In The Right Place At The Right Time

Seeking Alpha: Launch Delays The Wrong Prescription For GenMark Shares

Investors don't really have to look forward many years to value potential high-growth med-tech stories, but the consequences can be severe when those companies disappoint. GenMark Diagnostics (NASDAQ:GNMK) is certainly not the first or only diagnostics company to disappoint investors with delays in its commercialization timeline, but the confluence of a roughly half-year delay, ongoing progress at BioMerieux, and more risk aversion in the market has pushed the shares down about 40% since my last update.

The good news is that GenMark's ePlex system still compares quite favorably to systems from BioMerieux, Luminex (NASDAQ:LMNX), and Nanosphere (NASDAQ:NSPH) and the multiplex molecular diagnostics (or MDx) market is still very underpenetrated at hospital and reference labs. The bad news is that BioMerieux has done really well with system placements and the hospital diagnostics market is intensely competitive. GenMark does look undervalued today, but investors are looking at a wait of several years before there is meaningful revenue or cash flow and the risk here is well above average.

Continue here:
Launch Delays The Wrong Prescription For GenMark Shares

Seeking Alpha: After Some Turbulence, NuVasive Appears To Be On A Better Flightpath

I've liked NuVasive (NASDAQ:NUVA) for some time now, and the company's share price performance (up 12% from my last article in March, and up 48% since this article in the summer of 2014) has given me no cause for regrets. While the company has seen plenty of turmoil, including major departures of "C-suite" executives, the basic plan of driving increased market share, increased overseas sales, and better margins seems very much intact.

I continue to believe that NuVasive has a strong future. Minimally invasive procedures should continue to gain share within the large spinal procedure market, and I see little evidence that NUVA is losing its edge in terms of innovation and product development. The company does have the significant challenge of striking the right balance between growth-supportive spending and improved margins, but I think it has a credible plan to achieve both. M&A remains a big wildcard, both in terms of who/what NuVasive may buy and who may try to buy NuVasive.

A relative outperformer in a tough market, NuVasive doesn't leap out to me as a cheap stock today, but then again high-quality med-tech growth seldom sells cheaply. A mid-$50s fair value still looks reasonable on an EV/revenue basis, but the volatility of these shares may argue for a wider-than-average margin of safety for new buyers.

Read more here:
After Some Turbulence, NuVasive Appears To Be On A Better Flightpath

Seeking Alpha: As Getinge Embarks On Much-Needed Restructuring, A Lot Is Already In The Price

Turnarounds can be great opportunities for outsized returns, but that typically only holds true when the company in question is undervalued going into the turnaround process and/or the company exceeds its transformation goals. While Sweden's Getinge (OTCPK:GNGBY) could create additional value by exceeding its recently outlined restructuring goals, it is hard to call the shares undervalued absent that outperformance.

Continue here:
As Getinge Embarks On Much-Needed Restructuring, A Lot Is Already In The Price

Seeking Alpha: Chr Hansen Is A Rare Story In The Food Sector

On the whole, established companies in the food and beverage space don't typically grow their revenue at more than a low-to-mid single digit clip over the long term. But then, those companies aren't Denmark's CHR Hansen (OTCPK:CHYHY) and aren't leveraged to strong underlying trends in consumer preferences, as well as R&D-driven edges in customer costs and efficiency.

Not unlike Novozymes (OTCPK:NVZMY), CHR Hansen has almost everything I like to see in a company except for an attractive valuation. I do believe that the company has meaningful opportunities to leverage growth opportunities in dairy consumption, probiotics, natural colors, and agriculture, but the stock's valuation already reflects what I believe are generous assumptions regarding growth and the quality of the company.

I'd certainly monitor CHR Hansen in the hope of buying on a market freak-out (whether company-specific or across the market), but the shares today seem priced more for those who are comfortable buying growth almost irrespective of value.

Continue here:
Chr Hansen Is A Rare Story In The Food Sector

A Year of Cancer

This post has next-to-nothing to do with investing, so only read further if you're interested in more "personal" stuff. I originally posted this on Seeking Alpha, so you can read it there instead if you prefer.

Today is a year to the day that my wife was first diagnosed with cancer. It was a very sobering day; especially as I knew enough about this type of cancer to know how poor her chances were and are (perhaps luckily for her, she *didn't* know what she was getting into, and that probably helped preserve her optimism).

Since the time of diagnosis, there has been surgery, radiation, and three forms of chemo. Surgery addressed the immediate problem (a tumor that had grown from the size of an almond to a hockey puck in about five or six weeks), but most of the interventions have done little to help. The second round of chemo shrank the tumors, but that only lasted for about six months (bang in line with the median response). Now she's looking at the last proven therapeutic option for her type of cancer (or at least the last with a response rate that actually supports any hope).

A lot has changed. My productivity has plunged. I've gone from routinely writing about 1,000 articles a year to a pace where I may only halfway there this year. Funny how work really is a "habit".
A lot has also changed about how I look at healthcare and biotech/pharma. I wish there was more that the FDA could do to squash the frauds, crackpots, and scum who try to promote their phony fake cures for cancer and try to propagate myths about how "deadly" chemo is and how the healthcare system is simply trying to scam them.

I'm also grateful that there are doctors who choose to go into oncology - in effect choosing a field where they know they will lose a large number of patients instead of a specialty that offers far more certain positive outcomes on a regular basis.

Last and not least, I've learned how much months matter. Whether or not a drug that extends life by 6 months is "worth" $100,000 or more is a subject for another time, but those months matter a lot more when you're living through them one at a time. It's ridiculous that anybody in his or her early 40's should feel grateful to get another six months, but that's how it is.

On a related subject, it's interesting how much timing matters. If my wife had been diagnosed with this disease five years ago, none of her chemo options would have been available outside of clinical trials. In stark terms, she'd mostly likely be dead by now were that the case. Because of its complexity, I don't believe I'll live to see a point where cancer is like or HIV (serious, but very treatable/manageable) but given how much has changed just in the last five or 10 years, there's nevertheless hope that further improvements will come.

And when it comes down to it, hope gets you through a lot. I've learned that over the last year.

Seeking Alpha: Novozymes And The High Cost Of Greatness

When I first started the process of refreshing and updating my research on Danish enzyme specialist Novozymes (OTCPK:NVZMY), I was really hoping that the end result would be an undervalued and appealing investment opportunity. This is a company that I like a lot and a stock that I want to like. Now, readers can carp about whether wanting to like a company pollutes the research/analysis process, but I see no reason to hide the fact that I think Novozymes is a well-run company with a strong leadership position in a sizable but growing industry.

Valuation is the issue. I realize that investors should expect to pay up for quality, and Novozymes's nearly 50% market share in the industry and strong history of ROIC generation are certainly marks of quality, but I'm not comfortable with the sort of growth/certainty that appears to be factored into the valuation today. Investors less sensitive to valuation may find more to like here (particularly after the 20% decline from the 52-week high), as this is the sort of situation where price is really my only major hang-up.

Continue reading here:
Novozymes And The High Cost Of Greatness

Seeking Alpha: Hurco In A Tougher Patch, But Using Its Balance Sheet To Build

From SKF (OTCPK:SKFRY) to Kennametal (NYSE:KMT) to Fastenal (NASDAQ:FAST), there has been no shortage of data points confirming that the present environment for industrial tools and components is pretty lackluster. With that backdrop, there was no particular reason to think that Hurco (NASDAQ:HURC) was going to have a great quarter, but I would argue that this small machine tool company is doing better than the valuation would otherwise suggest.

Hurco's management has also chosen to make use of its strong balance sheet, acquiring two other machine tool companies that broaden its addressable market and should give HURC expanded sales and margin opportunities down the road. I realize some investors won't buy a cyclical company in the midst of the below-the-line part of the cycle, but I believe mid-single-digit long-term revenue growth and further margin leverage can support a fair value in the mid-$40s today, suggesting significant undervaluation that more than rewards the above-average risks.

Read the full article here:
Hurco In A Tougher Patch, But Using Its Balance Sheet To Build

Seeking Alpha: 'Steady As She Goes' Unlikely To Change The Sentiment On ABB

While some company boards seem to go to great lengths to accommodate institutional investors with their corporate strategies, others are more willing to endure skepticism and outright criticism in the pursuit of what they believe to be the right strategy. Time will tell if ABB (NYSE:ABB) is right to ignore calls to break up the company and/or dramatically remake this large power and automation equipment company, but today's Capital Markets Day makes it pretty clear that the board is not seeking to significantly change the direction of this company.

I view ABB's commitment to its strategy as a good news/bad news sort of dilemma for investors. In the short term, "same as it ever was" is not going to change the tone on this company. A tone influenced to no small degree by the significant weakness in the automation market, the as of yet unconfirmed recovery in power, and the company's less than stellar record of investing in innovation. Longer term, though, I continue to believe that the company's positions in power and automation are more valuable than the skeptics acknowledge and that low-to-mid single-digit growth is enough to support a fair value in the mid-$20s for the ADRs.

Continue here:
'Steady As She Goes' Unlikely To Change The Sentiment On ABB

Seeking Alpha: Multi-Color Remains Focused On A 'Rinse And Repeat' Business Model

I wouldn't say that label manufacturer Multi-Color (NASDAQ:LABL) is exactly toiling away in obscurity, as it has some big name institutional owners and sports a pretty healthy multiple, but this isn't the kind of business that typically attracts a lot of investor attention. That's fine as far as I'm concerned; labels aren't going away anytime soon, and Multi-Color still has a significant opportunity to consolidate the industry, improve its asset efficiency/utilization, and upgrade its product mix.

I believe that the Street has these shares more or less fairly valued today. I do believe that ongoing consolidation could offer some upside to my mid-single digit long-term revenue growth estimate, while better margins could likewise drive better free cash flow generation, but I already factor in what I think is a meaningful trajectory for self improvement. The company's issues with financial controls are a risk factor, particularly given the extent to which the company leans on M&A, but management does seem to be addressing this problem.

Read more here:
Multi-Color Remains Focused On A 'Rinse And Repeat' Business Model

Seeking Alpha: The Next 12 Quarters Should Say A Lot About Accuray

I don't typically like to talk about companies in "make or break" terms, but the next four quarters may be Accuray's (NASDAQ:ARAY) last, best hope for establishing itself as a legitimate growth story in radiation oncology. The company now has a fully-fledged product line-up and the marketing resources to get its name in front of radonc centers. Factoring in a (relatively) new trade-in program and the prospect for significant system renewals, the company really needs to hit its mark with quarterly orders to make a compelling case that it is a viable third player against Varian (NYSE:VAR) and Elekta (OTCPK:EKTAY).

Moving the model out a year boosts my DCF-based fair value estimate a bit above $9 while my revenue-based fair value stays around $12. That's meaningful undervaluation, but this is a company with an uninspiring record when it comes to disrupting the market and generating consistent order growth. I do believe that Accuray now offers reliable, capable, and differentiated systems that are appropriate for both multi-vault academic centers and smaller single/dual-vault community hospitals, but the next twelve months are a key proving ground for the company's sales effort and marketing message.

Read more here:
The Next 12 Quarters Should Say A Lot About Accuray